Kymera Therapeutics operates at the forefront of targeted protein degradation (TPD), developing oral small molecule therapies primarily for immune-inflammatory diseases. Its lead candidate KT-621, targeting STAT6, progresses through Phase 2b trials demonstrating promising biomarker and clinical signals. The company’s innovation is supported by prominent partnerships with Sanofi and Gilead, enhancing pipeline depth and validation. Despite accelerating R&D expenditures reflected in widening operating losses and negative cash flows, Kymera maintains a strong liquidity position bolstered by recent financings. Key risks remain from regulatory uncertainties inherent to novel modalities and the need for eventual commercial scale.